%0 Journal Article %A Mary E. Barecki %A Christopher N. Casciano %A William W. Johnson %A Robert P. Clement %T In Vitro Characterization of the Inhibition Profile of Loratadine, Desloratadine, and 3-OH-Desloratadine for Five Human Cytochrome P-450 Enzymes %D 2001 %J Drug Metabolism and Disposition %P 1173-1175 %V 29 %N 9 %X The purpose of this study was to evaluate loratadine, desloratadine, and 3-OH-desloratadine as inhibitors of certain human liver cytochrome P-450 enzymes. Pooled human liver microsomes were used to determine whether loratadine, desloratadine, and 3-OH-desloratadine were inhibitors of cytochrome P-450 (CYP) 1A2, 2C9, 2C19, 2D6, and 3A4. Loratadine did not inhibit CYP1A2 or CYP3A4 at concentrations up to 3829 ng/ml, which is approximately 815-fold greater than the expected maximal human plasma concentration (4.7 ± 2.7 ng/ml) following the recommended dose of 10 mg/day. Loratadine inhibited CYP2C19 and CYP2D6 with IC50 values of approximately 0.76 μM [291 ng/ml; Ki ≅ 0.61 μM (234 ng/ml)] and 8.1 μM [3100 ng/ml; Ki ≅ 2.7 μM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration. Neither desloratadine nor 3-OH-desloratadine inhibited CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 greater than 25% at concentrations of 3108 or 3278 ng/ml, respectively. These results suggest that loratadine and the active metabolites desloratadine and 3-OH-desloratadine are unlikely to affect the pharmacokinetics of coadministered drugs which are metabolized by these five cytochrome P-450 enzymes. The American Society for Pharmacology and Experimental Therapeutics %U https://dmd.aspetjournals.org/content/dmd/29/9/1173.full.pdf